Kindred Biosciences (KIN) Set to Announce Earnings on Tuesday

Kindred Biosciences (NASDAQ:KIN) is set to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect Kindred Biosciences to post earnings of ($0.36) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

KIN opened at $8.75 on Friday. The company has a market capitalization of $345.30 million, a PE ratio of -5.47 and a beta of 0.45. The firm’s 50 day simple moving average is $7.52 and its two-hundred day simple moving average is $7.81. Kindred Biosciences has a 1-year low of $5.96 and a 1-year high of $14.00. The company has a current ratio of 11.36, a quick ratio of 10.79 and a debt-to-equity ratio of 0.01.

A number of brokerages have commented on KIN. B. Riley cut shares of Kindred Biosciences from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $8.50 in a research note on Tuesday, July 16th. Zacks Investment Research raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday. ValuEngine raised shares of Kindred Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 15th. BidaskClub raised shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Kindred Biosciences in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $14.28.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: How Does the Quiet Period Work?

Earnings History for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.